Abstract
Mutations in phosphatase and tensin homologue (PTEN) or genomic alterations in the phosphatidylinositol-3-OH kinase-signalling pathway are the most common genetic alterations reported in human prostate cancer1,2,3,4. However, the precise mechanism underlying how indolent tumours with PTEN alterations acquire metastatic potential remains poorly understood. Recent studies suggest that upregulation of transforming growth factor (TGF)-β signalling triggered by PTEN loss will form a growth barrier as a defence mechanism to constrain prostate cancer progression5, underscoring that TGF-β signalling might represent a pre-invasive checkpoint to prevent PTEN-mediated prostate tumorigenesis. Here we show that COUP transcription factor II (COUP-TFII, also known as NR2F2)6,7,8,9, a member of the nuclear receptor superfamily, serves as a key regulator to inhibit SMAD4-dependent transcription, and consequently overrides the TGF-β-dependent checkpoint for PTEN-null indolent tumours. Overexpression of COUP-TFII in the mouse prostate epithelium cooperates with PTEN deletion to augment malignant progression and produce an aggressive metastasis-prone tumour. The functional counteraction between COUP-TFII and SMAD4 is reinforced by genetically engineered mouse models in which conditional loss of SMAD4 diminishes the inhibitory effects elicited by COUP-TFII ablation. The biological significance of COUP-TFII in prostate carcinogenesis is substantiated by patient sample analysis, in which COUP-TFII expression or activity is tightly correlated with tumour recurrence and disease progression, whereas it is inversely associated with TGF-β signalling. These findings reveal that the destruction of the TGF-β-dependent barrier by COUP-TFII is crucial for the progression of PTEN-mutant prostate cancer into a life-threatening disease, and supports COUP-TFII as a potential drug target for the intervention of metastatic human prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11–22 (2010)
Trotman, L. C. et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, E59 (2003)
Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209–221 (2003)
Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725–730 (2005)
Ding, Z. et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470, 269–273 (2011)
Pereira, F. A., Qiu, Y., Zhou, G., Tsai, M. J. & Tsai, S. Y. The orphan nuclear receptor COUP-TFII is required for angiogenesis and heart development. Genes Dev. 13, 1037–1049 (1999)
Takamoto, N. et al. COUP-TFII is essential for radial and anteroposterior patterning of the stomach. Development 132, 2179–2189 (2005)
You, L. R. et al. Suppression of Notch signalling by the COUP-TFII transcription factor regulates vein identity. Nature 435, 98–104 (2005)
Lin, F. J., Qin, J., Tang, K., Tsai, S. Y. & Tsai, M. J. Coup d’Etat: an orphan takes control. Endocr. Rev. 32, 404–421 (2011)
Qin, J., Chen, X., Yu-Lee, L. Y., Tsai, M. J. & Tsai, S. Y. Nuclear receptor COUP-TFII controls pancreatic islet tumor angiogenesis by regulating vascular endothelial growth factor/vascular endothelial growth factor receptor-2 signaling. Cancer Res. 70, 8812–8821 (2010)
Qin, J., Chen, X., Xie, X., Tsai, M. J. & Tsai, S. Y. COUP-TFII regulates tumor growth and metastasis by modulating tumor angiogenesis. Proc. Natl Acad. Sci. USA 107, 3687–3692 (2010)
Dhanasekaran, S. M. et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822–826 (2001)
Tomlins, S. A. et al. Integrative molecular concept modeling of prostate cancer progression. Nature Genet. 39, 41–51 (2007)
Nagasaki, S. et al. Chicken ovalbumin upstream promoter transcription factor II in human breast carcinoma: possible regulator of lymphangiogenesis via vascular endothelial growth factor-C expression. Cancer Sci. 100, 639–645 (2009)
Shin, S. W. et al. Clinical significance of chicken ovalbumin upstream promoter-transcription factor II expression in human colorectal cancer. Oncol. Rep. 21, 101–106 (2009)
Dyrskjøt, L. et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 64, 4040–4048 (2004)
Yeh, H. Y. et al. Identifying significant genetic regulatory networks in the prostate cancer from microarray data based on transcription factor analysis and conditional independency. BMC Med. Genomics 2, 70 (2009)
Jin, C., McKeehan, K. & Wang, F. Transgenic mouse with high Cre recombinase activity in all prostate lobes, seminal vesicle, and ductus deferens. Prostate 57, 160–164 (2003)
Padua, D. et al. TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133, 66–77 (2008)
Chen, M. et al. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell 20, 173–186 (2011)
Nakagawa, T. et al. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS ONE 3, e2318 (2008)
Chu, G. C., Dunn, N. R., Anderson, D. C., Oxburgh, L. & Robertson, E. J. Differential requirements for Smad4 in TGFβ-dependent patterning of the early mouse embryo. Development 131, 3501–3512 (2004)
Kruse, S. W. et al. Identification of COUP-TFII orphan nuclear receptor as a retinoic acid-activated receptor. PLoS Biol. 6, e227 (2008)
Ayala, G. et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin. Cancer Res. 10, 6572–6578 (2004)
Hodgson, M. C. et al. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res. 71, 572–582 (2011)
Agoulnik, I. U. et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 66, 10594–10602 (2006)
Wu, S. P., Lee, D. K., Demayo, F. J., Tsai, S. Y. & Tsai, M. J. Generation of ES cells for conditional expression of nuclear receptors and coregulators in vivo. Mol. Endocrinol. 24, 1297–1304 (2010)
Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209–221 (2003)
Feng, X. H., Liang, Y. Y., Liang, M., Zhai, W. & Lin, X. Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-β-mediated induction of the CDK inhibitor p15Ink4B. Mol. Cell 9, 133–143 (2002)
Li, L. et al. The nuclear orphan receptor COUP-TFII plays an essential role in adipogenesis, glucose homeostasis, and energy metabolism. Cell Metab. 9, 77–87 (2009)
Park, J. H. et al. Prostatic intraepithelial neoplasia in genetically engineered mice. Am. J. Pathol. 161, 727–735 (2002)
Creighton, C. J. et al. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS ONE 7, e34546 (2012)
The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011)
Creighton, C. J. et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J. Clin. Oncol. 26, 4078–4085 (2008)
Creighton, C. J. et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl Acad. Sci. USA 106, 13820–13825 (2009)
Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835–848 (2009)
Glinsky, G. V., Glinskii, A. B., Stephenson, A. J., Hoffman, R. M. & Gerald, W. L. Gene expression profiling predicts clinical outcome of prostate cancer. J. Clin. Invest. 113, 913–923 (2004)
Yu, Y. P. et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 22, 2790–2799 (2004)
Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11–22 (2010)
Acknowledgements
We thank H. Wu for the Ptenflox/flox mice, F. Wang for ARR2PB-Cre (PB-Cre) transgenic mice and E. J. Robertson for the Smad4flox/flox mice. We thank H. K. Graves and L.-Y. Yu-Lee for editorial assistance and S. Elledge for comments. We also thank the Baylor Microarray Core supported by the DERC Center (P30 DK079638) for the microarray analysis. This work was supported by grants from the National Institutes of Health DK62434, DK59820 (S.Y.T. and M.-J.T.), DK45641 (M.-J.T.) and HL76448 (S.Y.T.), and the Dan L. Duncan Cancer Center.
Author information
Authors and Affiliations
Contributions
J.Q., M.-J.T. and S.Y.T. conceived and designed the experimental approach, performed experiments and prepared the manuscript as senior authors. C.J.C. contributed to computational analysis for gene signature analysis and statistical analysis. A.F., G.A. and M.M.I. performed TMA and pathology analyses. S.-P.W. generated COUP-TFIIOE/+ mice. F.D., X.X. and C.-M.C. performed and X.-H.F., X.L. and S.-J.T. supervised a specific subset of experimental design and analysis.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Information
This file contains Supplementary Figures 1-14 and Supplementary Tables 1-5. (PDF 8144 kb)
Supplementary Data
This file contains Supplementary Data. (XLS 1083 kb)
Rights and permissions
About this article
Cite this article
Qin, J., Wu, SP., Creighton, C. et al. COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis. Nature 493, 236–240 (2013). https://doi.org/10.1038/nature11674
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature11674
This article is cited by
-
GATA2 co-opts TGFβ1/SMAD4 oncogenic signaling and inherited variants at 6q22 to modulate prostate cancer progression
Journal of Experimental & Clinical Cancer Research (2023)
-
An epigenetic switch controls an alternative NR2F2 isoform that unleashes a metastatic program in melanoma
Nature Communications (2023)
-
ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression
Nature Communications (2022)
-
CPSF4 promotes tumor-initiating phenotype by enhancing VEGF/NRP2/TAZ signaling in lung cancer
Medical Oncology (2022)
-
Long non-coding RNA NR2F2-AS1: its expanding oncogenic roles in tumor progression
Human Cell (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.